PLC Medical’s RenalGuard Reduces Kidney Damage From Imaging Dye
This article is for subscribers only.
A device developed by PLC Medical Systems Inc., the maker of equipment used in cardiac procedures, reduced the number of patients who developed kidney damage from a thick dye used to help peer into patient’s hearts and veins.
About 4 million patients in the U.S. and 3 million in Europe undergo cardiac procedures each year in which doctors inject a contrast dye into their veins to visualize the blood vessels with X-rays or other imaging methods, said Mark Tauscher, chief executive officer of Franklin, Massachusetts-based PLC.